COOK-MEDICAL
For UK distribution to professional audiences only
Please note that this press release is only provided to a selected circle of press members and should not be circulated to any other addressees. Its content is directed to professionals only and not consumers.
This document is offered to you to provide you with information for your own independent work.
Cook Medical will introduce European head and neck surgeons and otolaryngologists to its line of minimally invasive devices at the 2nd meeting of the European Academy of OtoRhinoLaryngology and Head Neck/Surgery (EAORL-HNS) .
Cook’s Otolaryngology/Head and Neck Surgery (OHNS) division will focus initially on six ear, nose and throat (ENT) practice areas. These areas are obstructive salivary gland disease, soft tissue repair, chronic rhinosinusitis, vocal cord paralysis, obstructive sleep apnoea and interventional airway and oesophageal procedures.
Said Thomas Cherry, global leader for Cook Medical’s OHNS division, “There are more than 25,000 ENT specialists in Europe.1 Our goal is to help show them the value of minimally invasive procedures and train them on how Cook’s devices can help patients. We are committed to serving European otolaryngologists and surgeons and their patients by helping to reduce the need for open surgery.”
Cook’s salivary duct access products include minimally invasive sialendoscopy tools. These include a soft-tip wire guide, Salivary Access Dilator Set, the Kolenda Salivary Access Introducer Set, and the NGage® Salivary Stone Extractor and NCircle® Salivary Stone Extractor.
Conference attendees will also see Cook’s Hercules® 3 Stage Esophageal Balloon designed to treat abnormal narrowing of the digestive tract. Additionally, Cook OHNS will launch the Chiba EchoTip® Biopsy Needle, a high-visibility needle that can be seen under ultrasound and is intended for use during thyroid gland biopsy.
Drawing on Cook’s long history of developing tissue-based acellular grafts, Cook OHNS will introduce the Biodesign® Dural Graft. This scaffold is intended to reduce the risk of cerebral spinal fluid leaks following cranial procedures. Biodesign grafts help the body to remodel native tissues using the patient’s own cells. The same technology is used in the Biodesign® ENT Surgical Reinforcement Graft, which is intended for implantation to reinforce soft tissue.
One EU surgeon has already used Cook’s Biodesign ENT Surgical Reinforcement Graft in his tympanoplasty procedures to repair punctured eardrums. Dr. Riccardo D'Eredità, Associate Director in the Department of Otorhinolaryngology, Head and Neck Surgery, at the Vicenza Civil Hospital in Italy will present an e-poster at the conference on his use of the graft, which is indicated for this use in the European Union.
He says, “Closing tympanic punctures can be difficult to treat. My initial experiences with Cook’s Biodesign ENT Surgical Reinforcement Graft have been positive and indicate that it could eliminate the need to harvest autologous tissue to repair these defects.”
Canadian head and neck surgeon Dr. Jack Kolenda will also present on percutaneous sialendoscopy using the new salivary duct access kit he developed with Cook. The new minimally invasive procedure allows physicians to treat blockages and remove stones from the salivary glands without performing open surgery, which carries a risk of facial paralysis.
“ This expansion shows our commitment to European ENT patients facing difficult treatment choices,” adds Pete Yonkman, executive vice president of strategic business units for Cook Medical. “Cook OHNS is bringing critical new products to market and training doctors in the procedures they’re used for. We hope to help more patients and touch more clinicians with this technology.”
Cook now has ten active clinical divisions in Europe: OHNS ; Aortic Intervention ; Critical Care ; Endoscopy ; Interventional Radiology ; Lead Management ; Peripheral Intervention ; Surgery ; Urology and Women’s Health .
Dr. Kolenda receives royalty payments based upon Cook’s license to use the Kolenda Salivary Access Introducer Set. Cook’s Biodesign Surgical Reinforcement Graft is not indicated for use in tympanoplasty in the United States at this time.
No. No. No.
ABOUT COOK MEDICAL
A pioneer in medical breakthroughs, Cook Medical is committed to creating effective solutions that benefit millions of patients worldwide. Today, we combine medical devices, drugs, biologic grafts and cell therapies across more than 16,000 products serving more than 40 medical specialties. Founded in 1963 by a visionary who put patient needs and ethical business practices first, Cook is a family-owned company that has created more than 10,000 jobs worldwide. For more information, visit www.cookmedical.com . Follow Cook Medical on Twitter and LinkedIn.
No. No. No.
1 Mollenhauer H.W. Union européenne des médecins specialists. ENT specialists within EU member states and associated countries . http://www.orluems.com/gestor/upload/ENT%20Specialists%20within%20EU%20member%20states%20and%20associated%20countries.pdf . Accessed April 16, 2013.
Contact:
Media Contacts:
Linda Murphy
Cook Medical, EU Public
Relations Manager
Office: +353 61 250 570
Mobile: +353 87 2448
531
Linda.Murphy@CookMedical.com
or
Alex
Gandhi
Racepoint Group, Senior Client Executive
Office: +44
208 811 2474
Mobile: +44 7874 995 917
Alex.Gandhi@RacepointGroup.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum